RETIMIX2020-05-20T16:39:17+02:00

Products – RETIMIX®

BOSWELLIA-PHYPHOLIPID 250 mg

CURCUMA-PHYPHOLIPID 250 mg

RETIMIX® is a food supplement with an innovative formula (Casperiva®) based on Indian oli-banum (Boswellia serrata) and Turmeric (Curcuma longa) and complexed within phytosomes

GLUTEN FREE

SUGAR FREE

The patented technology of Eye Pharma

INGREDIENTS

Casperiva®, a concentrated blend of synergistic active ingredients: boswelic acids and curcuminoids. Our patented system (Phytosome®) allows greater bioavailability of these active compounds.

DETAILS

The active ingredients,  boswellic acid and curcuminoids extracts, are complexed in phosphatidylcholine and phosphatidylserine in phytosomes. The synergy between these two extracts acts as mediators of chronic inflammation.  Boswellic acids belong to the triterpenoid family and include AKBA (3-Acetyl-11-keto-Beta-Boswellic Acid), while curcuminoids contain curcumin, demethoxicurcumin and bisdemethoxycurcumin.

INNOVATION

Oxidative stress and inflammation  are responsible for the damage to the RPE (retinal pigment epithelium) and choriocapillary associated with Age-related Macular Degeneration (AMD). When significant, such damages can cause AMD to develop into exudative macular degeneration (wet AMD). . Inflammation causes  other ophthalmic alterations, such as  the occurrence of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME).

The specific characteristics of the active ingredients of Retimix  aid conventional drug therapies in the treatment of eye degenerative diseases associated with multifactorial pathogenesis that is dependent on the combination of inflammatory and angiogenesis processes.

Casperiva® is an Eye Pharma SpA brand
Phytosome® is an Indena SpA brand

TECNOLOGY

ABOUT RETIMIX®

NEWS AND INSIGHTS

WET AGE-RELATED MACULAR DEGENERATION (AMD): PHARMACOLOGICAL THERAPIES (INTRAVITREAL INJECTIONS)

Intravitreal injections, performed by a qualified ophthalmologist, allow placing a specific drug directly into the space in the back of the eye …

HYPERGLYCEMIA AND DAMAGE TO THE RETINAL BLOOD VESSELS

Unhealthy lifestyle and eating habits have been considered the main risk factors for the development of diabetes, a serious health condition. Diabetic retinopathy is a diabetes complication caused by …

THE EVOLUTION OF THE PHYTOSOME TECHNOLOGY

Thanks to the phytosome technology, it is possible to combine two phospholipids together into an innovative formulation. As a result, the specific properties of each phospholipid …

Le informazioni, immagini, descrizioni e quanto altro riportato nel sito relativi a dispositivi medici non sono di natura pubblicitaria ma materiale informativo rivolto esclusivamente a Professionisti dell’area sanitaria. Pertanto proseguendo nella navigazione l’utente dichiara di essere un Professionista dell’area sanitaria. Riferimento:Ministero della Salute – “Nuove linee guida della pubblicità sanitaria concernente i dispositivi medici, dispositivi medico-diagnostici in vitro e presidi medico-chirurgici” del 28 Marzo 2013; Aggiornamento delle “Linee guida in merito all’utilizzo di nuovi mezzi di diffusione della pubblicità sanitaria” del 17 Febbraio 2010 - These statements have not been evaluated by the Food & Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Please contact your healthcare professional immediately if you experience any unwanted side effects. The information contained herein is for informational purposes only and does not establish a doctor-patient relationship. Please be sure to consult your physician before taking this or any other product. Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.
Go to Top